ストックスクリーナーアプリを入手
1.065
24.20%
-0.34
プレマーケット:
1.03
-0.035
-3.29%
Outlook Therapeutics Inc (OTLK) 最新ニュース
OTLK|Outlook Therapeutics Inc|Price:1.065|Chg%:-0.340 - TradingKey
Outlook Therapeutics Inc (OTLK) Institutional Confidence - TradingKey
OTLK Maintained by HC Wainwright & Co. -- Price Target Raised to $1.60 - GuruFocus
Outlook Therapeutics’ Recently Approved Therapy Could Become Preferred Anti-VEGF Treatment Option In $8.5B US Retina Market, Says BTIG - Stocktwits
These 3 Stocks Led Wall Street’s Biggest Gains On Tuesday – Here’s Why - Stocktwits
OTLK Upgraded by BTIG -- Price Target Announced at $4.00 - GuruFocus
Outlook Therapeutics Targets Multibillion Dollar Ophthalmology Market With New Drug After FDA Rejection - Benzinga
BTIG upgrades Outlook Therapeutics stock rating on FDA approval - Investing.com
FDA nod for Outlook Therapeutics’ Lytenava at last - The Pharma Letter
This General Motors Analyst Turns Bulish; Here Are Top 5 Upgrades For Monday - Benzinga
Outlook Therapeutics wins FDA approval for Lytenava in wet AMD - Yahoo Finance
Outlook Therapeutics shares climb after FDA clears LYTENAVA for wet AMD - Yahoo Finance
BTIG upgrades Outlook Therapeutics stock rating on FDA approval By Investing.com - Investing.com Canada
Why is Outlook Therapeutics stock surging today? By Investing.com - Investing.com Canada
OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug — Analysts See Nearly 300% Upside - Stocktwits
FDA Approves Outlook Therapeutics’ Lytenava to Treat Wet AMD - VisionMonday.com
Outlook Therapeutics Inc (OTLK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OTLK Stock Surges After FDA Ends Decade-Long Wait For Ophthalmic Bevacizumab - Stocktwits
OTLK Stock Soars 28% After FDA Sets July Date For Lytenava Decision - Stocktwits
Outlook Therapeutics Inc (OTLK) Income Statement - TradingKey
OTLK Stock Surges On FDA Lytenava Application Resubmission After Successful Appeal - Stocktwits
FDA Finally Clears Outlook Therapeutics' Lytenava, But the Cash Crunch Looms Large - AD HOC NEWS
Outlook Therapeutics Grants Incentive Awards Tied to FDA Approval - The Globe and Mail
Outlook Therapeutics Inc (OTLK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
US FDA approves Outlook Therapeutics’ eye disease drug - KWSN
Outlook Therapeutics (OTLK) Receives FDA Approval for Lytenava i - GuruFocus
Outlook Therapeutics (OTLK) Secures FDA Approval for Lytenava in Wet AMD Treatment - GuruFocus
OTLK Stock Surges 24% Following FDA Approval for AMD Treatment - GuruFocus
Outlook Therapeutics Inc (OTLK) Valuation: PE, PB & Fair Value Analysis - TradingKey
Outlook Therapeutics Gains FDA Approval for LYTENAVA Launch - TipRanks
US FDA approves Outlook Therapeutics' eye disease drug - Reuters
OTLK Stock Slips After Regaining Nasdaq Compliance - timothysykes.com
FDA approves Outlook Therapeutics' LYTENAVA for the treatment of wet AMD - Ophthalmology Times Europe
Outlook Therapeutics (OTLK) Receives FDA Approval for Lytenava in Wet AMD Treatment - GuruFocus
Outlook Therapeutics (NASDAQ:OTLK) suspended post-Lytenava approval, with funding under pressure from looming warrants - TechStock²
Outlook Therapeutics receives FDA approval for wet AMD treatment - Investing.com
Outlook Therapeutics Says Lytenava Gets FDA Approval for Retinal Disease Treatment - marketscreener.com
FDA Approves Outlook Therapeutics' Lytenava as First Ophthalmic Bevacizumab for Wet AMD - Eyewire+
Outlook Therapeutics Announces LYTENAVA FDA Approval For Treatment Of Wet AMD - TradingView
US-FDA genehmigt Medikament von Outlook Therapeutics gegen Augenerkrankungen - TradingView
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as - GlobeNewswire
Outlook Therapeutics, Inc. Revenue Breakdown – SWB:41O - TradingView
Outlook Therapeutics grants options to CEO Robert C. Jahr and CFO Lawrence A. Kenyon - TradingView
Form 4 OUTLOOK THERAPEUTICS INC For: 23 July By Investing.com - Investing.com Nigeria
Outlook Therapeutics grants CEO, CFO options at $1.43 per share - Bitget
Outlook Therapeutics (NASDAQ: OTLK) grants 210,078 stock options to CFO - Stock Titan
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):